Vol. 21/No. 17 | Oncology Live®

September 06, 2020

One of the main methods to address this disparity of cancer care is using community health workers and navigators to do the grassroots outreach.

September 05, 2020

Under a draft recommendation proposed by the US Preventive Services Task Force, individuals who are at a high risk for developing lung cancer because of their smoking history would begin annual screening with low-dose computed tomography at aged 50 years.

September 04, 2020

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

September 03, 2020

Precision medicine advancements are opening a new chapter in the development of anticancer therapies that target the HER2 pathway, resulting in 3 approvals for breast cancer in less than a year and raising hopes for attacking other cancer types.

September 03, 2020

Investigators at UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, have launched a clinical trial to determine the impact on patient outcomes of stopping therapy after 1 year.

September 02, 2020

Priyanka Sharma, MD, discusses how data from early clinical studies suggest a role for CDK4/6 inhibitor-based combinations in hormone receptor- positive, HER2-positive breast cancer and triple-negative breast cancer.

September 02, 2020

Technological advancements are rapidly expanding the potential uses for blood-based liquid biopsies, but broad clinical adoption in cancer care hinges on improving the knowledge base of practicing oncologists and gathering prospective data to validate assays.

September 01, 2020

The approval of encorafenib in combination with cetuximab advances the metastatic colorectal cancer paradigm, introducing a biomarker-specific regimen for patients with pretreated BRAF V600E–mutant disease.

September 01, 2020

During an OncLive Peer Exchange®, a panel of orthopedic experts provided a comprehensive overview of these tumors, including their epidemiology and differential diagnosis, optimal clinical workup, and the role of surgical management.

August 29, 2020

When is it appropriate to accept a specific strategy, either formally or informally, as a standard-of-care option in managing the treatment of patients with cancer in a particular clinical setting?